Adverse Drug Event Clinical Trial
Official title:
Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
Several drugs and chemotherapies seem to have an impact on the immune system. This study investigates reports of immune toxicities such as antiphospholipid syndrome, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Several drugs and chemotherapies seem to have an impact on the immune system and are responsible of a wide range of immune side effects such as antiphospholipid syndrome. Those are poorly described, due to the modificationof the pharmacopeia, and the recent recognition of several of these adverseevents. This study investigates the main characteristics of patients affected by immune side effects imputed to drugs in particular antiphospholipid syndrome. A causality assessment according to the WHO-UMC (World Health Organization - Uppsala Monitoring Center) is systematically applied. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
| Completed |
NCT05007041 -
Simultaneous RZV and aIIV4 Vaccination
|
Phase 4 | |
| Suspended |
NCT02559960 -
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
|
||
| Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
| Completed |
NCT03112083 -
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
|
N/A | |
| Completed |
NCT05028361 -
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
|
Phase 4 | |
| Completed |
NCT04284553 -
Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
|
N/A | |
| Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
| Completed |
NCT04181775 -
Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
|
||
| Completed |
NCT02906657 -
Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly
|
N/A | |
| Completed |
NCT03640273 -
Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
|
Phase 2 | |
| Completed |
NCT02162147 -
How Safe Are Our Pediatric Emergency Departments?
|
N/A | |
| Completed |
NCT01897870 -
The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.
|
N/A | |
| Completed |
NCT03725046 -
Impact of an Optimized Communication on the Readmission for Adverse Drug Event
|
N/A | |
| Recruiting |
NCT04635956 -
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
|
Phase 2 | |
| Active, not recruiting |
NCT05538065 -
NUDGE-EHR Replication Trial at Mass General Brigham
|
N/A | |
| Completed |
NCT03442010 -
Adverse Drug Events at Emergency Department
|
||
| Recruiting |
NCT04791150 -
Rheumatologic Adverse Events and Cancer Immunotherapy
|
N/A | |
| Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
| Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A |